Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...
The Motley Fool on MSN3d
2 Hot Biopharma Stocks to Buy and Hold for 5 YearsSummit Therapeutics (NASDAQ: SMMT) is a biotech stock that few investors have heard of, but it has the makings of a winner ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback